These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 31654923)

  • 1. The effect of anticholinergic burden on cognitive and daily living functions in patients with schizophrenia.
    Kim SJ; Jung D; Shim JC; Moon JJ; Jeon DW; Kim YN; Seo YS; Jung SS; Seo BJ; Kim JE
    Asian J Psychiatr; 2019 Dec; 46():111-117. PubMed ID: 31654923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticholinergic Burden and Cognition in Older Patients With Schizophrenia.
    Tsoutsoulas C; Mulsant BH; Kumar S; Ghazala Z; Voineskos AN; Menon M; Pollock BG; Rajji TK
    J Clin Psychiatry; 2017; 78(9):e1284-e1290. PubMed ID: 29188908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impact of Medication Anticholinergic Burden on Cognitive Performance in People With Schizophrenia.
    Ang MS; Abdul Rashid NA; Lam M; Rapisarda A; Kraus M; Keefe RSE; Lee J
    J Clin Psychopharmacol; 2017 Dec; 37(6):651-656. PubMed ID: 29016375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticholinergic Medication Burden-Associated Cognitive Impairment in Schizophrenia.
    Joshi YB; Thomas ML; Braff DL; Green MF; Gur RC; Gur RE; Nuechterlein KH; Stone WS; Greenwood TA; Lazzeroni LC; MacDonald LR; Molina JL; Nungaray JA; Radant AD; Silverman JM; Sprock J; Sugar CA; Tsuang DW; Tsuang MT; Turetsky BI; Swerdlow NR; Light GA
    Am J Psychiatry; 2021 Sep; 178(9):838-847. PubMed ID: 33985348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive burden of anticholinergic medications in psychotic disorders.
    Eum S; Hill SK; Rubin LH; Carnahan RM; Reilly JL; Ivleva EI; Keedy SK; Tamminga CA; Pearlson GD; Clementz BA; Gershon ES; Keshavan MS; Keefe RSE; Sweeney JA; Bishop JR
    Schizophr Res; 2017 Dec; 190():129-135. PubMed ID: 28390849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticholinergic burden in schizophrenia and ability to benefit from psychosocial treatment programmes: a 3-year prospective cohort study.
    O'Reilly K; O'Connell P; Donohoe G; Coyle C; O'Sullivan D; Azvee Z; Maddock C; Sharma K; Sadi H; McMahon M; Kennedy HG
    Psychol Med; 2016 Nov; 46(15):3199-3211. PubMed ID: 27576609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial.
    Keefe RS; Fox KH; Harvey PD; Cucchiaro J; Siu C; Loebel A
    Schizophr Res; 2011 Feb; 125(2-3):161-8. PubMed ID: 21075600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling the effects of treatment resistance and anticholinergic burden on cognitive function domains in patients with schizophrenia.
    Chan SKW; Pang TSW; Tsui HKH; Suen YN; Yan WC; Tsui CF; Poon LT; Chan CWH; Lo A; Cheung KM; Hui CLM; Chang WC; Lee EHM; Chen EYH; Honer WG
    Psychiatry Res; 2024 Jul; 337():115985. PubMed ID: 38820652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of an extrinsic motivator on the evaluation of cognitive and daily living functions in patients with schizophrenia.
    Kim SJ; Jung DU; Moon JJ; Jeon DW; Seo YS; Jung SS; Lee YC; Kim JE
    Schizophr Res; 2020 Jun; 220():172-178. PubMed ID: 32241751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between disability self-awareness and cognitive and daily living function in schizophrenia.
    Kim SJ; Jung DU; Moon JJ; Jeon DW; Seo YS; Jung SS; Lee YC; Kim JE; Kim YS
    Schizophr Res Cogn; 2021 Mar; 23():100192. PubMed ID: 33294392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Developing clinical cut-off scores for the university of California San Diego performance-based skills assessment in patients with schizophrenia.
    Park SY; Jung DU; Kim SJ; Shim JC; Moon JJ; Jeon DW; Kim YN; Seo YS; Jung SS; Seo BJ; Kim JE
    Asian J Psychiatr; 2020 Jan; 47():101844. PubMed ID: 31665699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Anticholinergic Drug Burden with Cognitive and Functional Decline Over Time in Older Inpatients: Results from the CRIME Project.
    Brombo G; Bianchi L; Maietti E; Malacarne F; Corsonello A; Cherubini A; Ruggiero C; Onder G; Volpato S
    Drugs Aging; 2018 Oct; 35(10):917-924. PubMed ID: 30191516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of the α7-Nicotinic Acetylcholine Receptor Agonist ABT-126 in the Treatment of Cognitive Impairment Associated With Schizophrenia: Results From a Phase 2b Randomized Controlled Study in Smokers.
    Haig GM; Wang D; Zhao J; Othman AA; Bain EE
    J Clin Psychiatry; 2018; 79(3):. PubMed ID: 28922590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticholinergic drugs and functional, cognitive impairment and behavioral disturbances in patients from a memory clinic with subjective cognitive decline or neurocognitive disorders.
    Dauphinot V; Mouchoux C; Veillard S; Delphin-Combe F; Krolak-Salmon P
    Alzheimers Res Ther; 2017 Aug; 9(1):58. PubMed ID: 28764796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticholinergic Burden and Functional Status in Older People with Cognitive Impairment: Results from the Regal Project.
    Boccardi V; Baroni M; Paolacci L; Ercolani S; Longo A; Giordano M; Ruggiero C; Mecocci P
    J Nutr Health Aging; 2017; 21(4):389-396. PubMed ID: 28346565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atropinic (anticholinergic) burden in antipsychotic-treated patients.
    Montastruc F; Benevent J; Touafchia A; Chebane L; Araujo M; Guitton-Bondon E; Durrieu G; Arbus C; Schmitt L; Begaud B; Montastruc JL
    Fundam Clin Pharmacol; 2018 Feb; 32(1):114-119. PubMed ID: 28887902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of the University of California San Diego Performance-Based Skills Assessment for the evaluation of cognitive function and activities of daily living function in patients with cognitive impairment.
    Jeon DW; Ju HB; Jung DU; Kim SJ; Shim JC; Moon JJ; Kim YN
    Aging Ment Health; 2019 Jan; 23(1):46-52. PubMed ID: 29068696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of antipsychotic and anticholinergic medications on cognition in chronic patients with schizophrenia.
    Haddad C; Salameh P; Sacre H; Clément JP; Calvet B
    BMC Psychiatry; 2023 Jan; 23(1):61. PubMed ID: 36694187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: comparison of the anticholinergic cognitive burden scale and anticholinergic risk scale: results from the REPOSI study.
    Pasina L; Djade CD; Lucca U; Nobili A; Tettamanti M; Franchi C; Salerno F; Corrao S; Marengoni A; Iorio A; Marcucci M; Violi F; Mannucci PM
    Drugs Aging; 2013 Feb; 30(2):103-12. PubMed ID: 23239364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An optimal combination of MCCB and CANTAB to assess functional capacity in older individuals with schizophrenia.
    Kumar S; Mulsant BH; Tsoutsoulas C; Ghazala Z; Voineskos AN; Bowie CR; Rajji TK
    Int J Geriatr Psychiatry; 2016 Oct; 31(10):1116-23. PubMed ID: 27428251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.